Company intelligence / Profile preview

Evolus, Inc.

Newport Beach, California, United Statesevolus.com ↗

Ownership: Public · EOLS
Employees: ~332
Development stage: Commercial

Overview

Evolus has a commercially available neurotoxin product Jeuveau® (prabotulinumtoxinA-xvfs) for temporary improvement of moderate to severe frown lines. The company recently announced positive topline results from a pivotal trial for its first two Evolysse™ dermal filler products and plans to submit Premarket Approval applications to the FDA within 90 days as of May 2024.

Therapeutic areas: Dermatology
Modalities: NeurotoxinsDermal Fillers
Industry: Biotech

Drug pipeline

2 assets

prabotulinumtoxinA-xvfs

Commercial

Indications: Glabellar lines

1 more asset in the full pipeline.

Request access →

Financials

Market cap: $564.4M
Total revenue: $84.1M
Enterprise value: $684M

Beyond the preview

Go deeper on Evolus, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Evolus, Inc..

Explore the full profile